Starting treatment for early Alzheimer's disease has meant a standing appointment at an infusion center every two weeks for 18 months before any other option existed. That is changing. The FDA has approved a subcutaneous starting dose of lecanemab that eligible patients can receive at home, and the product is expected to become available in late August.
Previously, the subcutaneous form was approved only for maintenance, after 18 months of intravenous treatment. The approval announced by Eisai and Biogen extends it to initiation, meaning a patient can begin the entire course without an infusion.
